Business
Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent Chairman
MILAN & MORRISTOWN, N.J., March 24, 2025--Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent Chairman
About this update from Newron Pharmaceuticals S.p.a.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":281,"url":"https://media.zenfs.com/en/business-wire.com/fa5de60ad208a52b9f208cfcfb1823aa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wzCq9OJTSO95Fbql7Ktj1w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/fa5de60ad208a52b9f208cfcfb1823aa","width":480,"height":281}},"lazy":false},{"type":"text","content":"Expected to succeed Dr. Ulrich Köstlin who has notified Newron of his intention to retire after 12 years of service as Chairman of its Board of Directors, effective following completion of this year’s AGM","length":204,"tagName":"p","attribs":{}},{"type":"text","content":"Chris Martin, former CEO of ADC Therapeutics, will be proposed for election as Independent Non-Executive Director and new Chairman of the Board of Directors at Newron’s upcoming AGM","length":181,"tagName":"p","attribs":{}},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p","attribs":{}},{"type":"text","content":"MILAN & MORRISTOWN, N.J., March 24, 2025--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for diseases of the central and peripheral nervous system, today announced that its Board of Directors has identified Chris Martin, DPhil, as a potential Independent Non-Executive Director and Chairman of the Board and will propose him for election at Newron’s upcoming Annual General Meeting (AGM), to be held on April 23, 2025, in Bresso (Mi), Italy. Martin is an accomplished public and private company director with deep expertise in commercial drug development and a proven track record in founding and leading successful biopharma companies. He is expected to succeed Ulrich Köstlin, who has served as Chairman of the Board since 2013. Köstlin will end his board service following the completion of this year’s AGM.","length":934,"tagName":"p"},{"type":"text","content":"Dr. Chris Martin is a recognized leader in the biopharma industry who has taken therapeutic technology from the lab bench through to regulatory approval and global market sales. Over his career, he has raised more than $1.4 billion on the ca...